ReviewAmerican journal of hypertension2025
A Heart-to-Heart With ChatGPT: AI Applications in Hypertension.
Review in American journal of hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial Intelligence in Cardiovascular Medicine: Focus on Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Pooled it
- Application of AI in Hypertension Health Education: Scoping Review.Journal of medical Internet research · 2026Article
- Retrospective comparison of ChatGPT-4 treatment recommendations with real-world physician management in newly diagnosed hypertension: a single-centre study.Frontiers in cardiovascular medicine · 2026Article
- Artificial Intelligence in Healthcare: A Narrative Review of Recent Clinical Applications, Implementation Strategies, and Challenges.Journal of healthcare leadership · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major contributor to cardiovascular disease and premature mortality. Yet despite extensive research, aspects of the disease remain incompletely understood. Indeed, even with the availability of numerous medications, achieving optimal blood pressure control continues to be a challenge for some patients. These challenges may be attributable to the inherent heterogeneity in disease phenotype and to comorbidities. The recent explosion in healthcare data has presented an opportunity for progress: Artificial intelligence (AI), which is particularly adept in identifying patterns and regularity in a dataset, may facilitate a breakthrough in hypertension. This review summarizes the ways in which AI has transformed clinical practices, patient care, medical education, and research methodologies in hypertension. The focus of the review is on ChatGPT, an AI-powered conversational model that has enhanced data analysis, decision support, and patient education and has the potential to revolutionize hypertension research, diagnosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.